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Background : Cervical cancer is the second commonest gynaecological cancer amongst women worldwide and 
the leading cause of cancer deaths in developing countries – contributing 83% of new cases and 85% of all 
deaths annually to the burden of this disease.  Information and awareness of this illness in the developing world 
is still inferior, and mortality is increasing. In the developing world, late presentation, advanced-stage disease 
and a poorly run screening programme (covering only 55% of the South African population) are all contributing 
factors to this statistic. Approximately 20% of all South African women in their reproductive age are also HIV 
positive. With the rising burden of cervical cancer and the emergence of HIV as an influencing comorbidity, 
South Africa adopted a national cervical screening programme, rolled out in 2000 as well as an HCT (HIV 
counselling and testing) programme formalised in 2011. With these initiatives now in place, this study 
examined trends and compared 5-year survival outcomes between two decades for cervical cancer among 
young women.  
 
Methods : The study undertook a retrospective audit of files and information on the pre-existing cervical cancer 
database, and appropriate data was extracted (HREC REF 344/2011). Survival and disease outcomes at five 
years, as well as time to recurrence, was assessed, together with other demographics of the study population. 
Patients included in the study were non-pregnant female patients, aged 40 years and younger at the time of 
registration with the Groote Schuur Hospital (GSH) Oncology Unit (LE 33). The diagnosis of cervical cancer had 
to have been confirmed histologically, as either squamous cell carcinoma or adenosquamous carcinoma or 
adenocarcinoma. Patients must have attended at the LE 33 unit on or from 1 January 1993 until and including 
31 December 2012. The two decades were studied and 5-year outcomes from each decade were analysed and 
reviewed using Kaplan-Meier curves and univariate analyses. The study compared data using Log Rank tests 
and p-values.  
 
Findings : The two decade-groups under study showed no difference in trends of survival regarding age, 
treatment type and histology. Albeit small numbers, adenocarcinoma was the histology that had the best 
probability of survival during both decades. There were more patients with early-stage cancer (stage 1 and 2) 
diagnosed in decade B (2003 – 2012) than A (1993 – 2002). Within this early-stage cervical cancer cohort, there 
is a trend toward more locally-advanced (stage 2) cancer in the more recent decade. The proportion of patients 
presenting with stage 1a and 1b cancer with tumours 4 cm and less has halved from decade A to decade B. The 
proportion of stage 2 cancers presenting with tumours 2 – 4cm in size during decade B has risen almost 3-fold 
to that of decade A. This suggests a developing trend of presentation of more locally-advanced cancer. During 
both decades, stage 1 cervical cancers had the best probability of survival, with an improvement in mean 
survival from decade A (average of 44 months) to decade B (average of 58 months). The trend of stage 2 
disease has deteriorated, with a decrease in mean survival (from 48 months in decade A to 21 months in 
decade B), an increase in cancer-related deaths and a shorter time to relapse. The number of patients 
presenting with late-stage disease (stages 3 and 4) has declined. HIV positive status played an influential role in 
tumour size on presentation and probability of 5-year disease-free survival. Young women who were HIV 
positive also fared less favourably when compared to NP (not positive) women in terms of mean survival. Due 
to the small sample size and that the majority of patients in decade A were untested, further HIV comparisons 
were not credible. 
 
Interpretation : The study suggests a moving trend towards young patients that are being diagnosed with the 
more locally-advanced early-stage disease in the more recent decade than ten years prior. HIV status seemingly 
played an influential comorbid role in patients diagnosed with cervical cancer. Patients with the locally-
advanced disease appear to have worse outcomes in the latter decade. In an attempt to curb this potentially 
curable disease in this subset of young women, a greater focus on earlier screening interventions, prompt 
diagnosis and appropriate and timeous treatment of cervical cancer, together with optimisation of 





It is long since known that the human papilloma virus (HPV) is central to the development of 
cervical neoplasia and can be detected in up to 99,7% of cervical cancer cases.1 Many high-
risk HPV genotypes have been identified: subtypes “16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 73 and 82” have all been linked to cervical cancer with varying virulence.2 HPV type 
16 and 18 on their own are responsible for 70% of all cervical cancers and 50% of cervical 
cancer precursors worldwide and hence are the main pathogens.3 Worldwide, HPV infection 
is known to be the most common sexually transmitted infection (STI). Four out of every five 
sexually active women will have the virus at some point in their lives.1 Most women will be 
asymptomatic and will undergo natural elimination of HPV infection because of a healthy 
and intact immune system. Persistent infection with a high-risk HPV type puts women at risk 
to develop precursors of cervical cancer or overt cancer itself. In South Africa, as part of 
public health response to this severe problem, the HPV vaccine (Cervarix®) was rolled out in 
April 2014 to school-going girls, aged nine and older, at all public schools. The use of such 
vaccines still raises many unanswered questions in many respects.4  
 
HPV, transmitted easily through sexual intercourse, enters the basal layer of the cervical 
epithelium at sites of trauma. Once infected with HPV, the cervix reacts by undergoing mild 
cytological changes and abnormalities. The persistence of high-risk HPV over time results in 
transformations leading to cervical cancer. Once HPV integrates into the host genome, 
cytological screening can pick up these changes. Histologically, the genetic aberration is 
called cervical intraepithelial neoplasia (CIN) and can eventually progress to overt cervical 
carcinoma, if left untreated. The most common histological subtypes are squamous cell 
carcinoma (comprising 69% of total cervical cancers) and adenocarcinoma including 
adenosquamous carcinoma (25% of all cervical cancers).5,6 
 
As per the latest GLOBOCAN (Global Cancer Observatory) statistics in September 2018, the 
data estimated that the cancer burden had increased to 18,1 million cases and 9,6 million 
deaths, globally. These GLOBOCAN data estimates released in 2018 is based on an online 
database containing estimates of incidence and mortality in 185 countries for 36 cancer 
types. 7 As it stands, cervical cancer is the second commonest gynaecological cancer 
amongst women worldwide and the “leading cause of cancer-related deaths in developing 
countries”.8 In these countries, 83% of new cases and 85% of all deaths contribute annually 
to the burden of this disease.  In Sub-Saharan Africa (SSA), cervical cancer is rated as the 
most common cancer among women. Information and awareness of this illness in these 
areas are still inferior, and mortality seems to be on the incline.9 Delayed presentation, 
advanced stage of the disease and a poorly functioning screening process are all 




In an attempt to curb these demographics, in 2000 the South African National Department 
of Health (DoH) introduced a policy in which every South African woman is entitled to three 
pap smear tests in her lifetime, done every ten years, starting at the age of 30 (DoH, 2000).  
This move shows recognition of the severity of the rate of cervical cancer in the country, and 
a commitment from the government to help rectify the situation and improve statistics.  As 
part of its Women’s Health Programme, the DoH’s report puts screening as a vital mediation 
in the prevention of cervical cancer. In SA, a cervical cancer screening rate of 55% was 
achieved in the year 2011/2012 (DoH, 2012), in comparison to first-world countries where 
the current screening rate is 72%.10 The president of the International Gynaecological 
Cancer Society stressed that cancer prevention efforts should be an imperative focus for 
countries, as it is anticipated that by 2025 cancer will be a major cause of mortality across all 
populations.11,12  
 
Table 1 gives a timeline of the legislative and policy changes in South Africa, which has had 
an influence on reproductive health in the country. 
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Table 1:  Major Legislative and Policy Changes Influencing Reproductive Health in South 
Africa   (Source:  Ten Years of Democracy in South Africa:  Documenting Transformation in 
Reproductive Health Policy and Status)13 
 
From the timeline, it is evident that after 1993 the SA government together with the Centre 
for Disease Control (CDC) became more involved and active with the prevention and 
treatment of HIV and AIDS-defining illnesses – inclusive of invasive cervical cancer.14 In 
2000, the national cervical screening programme, commonly referred to as the "30-40-50" 
screening rule, began being rolled out. In April 2011 the South African government started 
the HIV Counselling and Testing (HCT) movement, a new national campaign to encourage 
people to know their HIV status and to access counselling and treatment including cervical 
screening.  
Major legislative and policy changes influencing reproductive health in South Africa 
1994 - Department of Health establishes partnerships to plan, process and review HIV/AIDS policy, focusing on the prevention  
of new HIV infections and treatment of AIDS-related opportunistic infections 
  - Free public health services for pregnant women and children under six 
1995 - Government ratifies the United Nations Convention on the Elimination of All Forms of Discrimination Against Women  
(CEDAW) 
1996 - Choice on Termination of Pregnancy Act provides a legal framework for the provision of abortion services 
1997 - Maternal death made a notifiable condition; Standing National Committee for Confidential Enquiries into Maternal  
Deaths established 
 - Patients’ Rights Charter launched, giving patients the knowledge and right to address issues of quality in health care  
services 
1998 - New Population Policy introduced, delinked from population growth 
 - South African National AIDS Council formed 
 - Domestic Violence Act passed 
1999 -  Prevention of Mother-to-Child Transmission (PMTCT) of HIV programmes introduced in the Western Cape province  
2000 - National Guidelines for Cervical Screening Programme launched 
2001 - PMTCT programme introduced in Gauteng province 
2002 -  Treatment Action Campaign and Children's Right Centre win a court application ordering the government to implement 
 a comprehensive PMTCT programme to prevent Mother-to-Child HIV transmission and to roll out PMTCT services  
country-wide 
 - National Contraception Policy Guidelines launched 
 - Government approves the provision of HIV post-exposure prophylaxis to survivors of rape in public sector facilities 
2003 - Government approves plan to provide antiretroviral drugs to people with AIDS through public sector services 







The rate of cervical cancer has declined markedly in settings with active cervical cancer 
screenings. On its own, the sensitivity of the Pap smear is approximately 54%.1 The newer 
screening methods, like HPV-DNA testing, are not yet available in the public sector in South 
Africa. HPV testing is also not yet implemented consistently in the private sector. In 
developed countries, women are screened every three years for cervical cancer from the 
age of 21 years (or at the age of sexual debut) until the age of 65 years. Co-testing with 
cytology and HPV-testing is encouraged from the age of 30, every five years.15,16 As per the 
National Cancer Institute, co-testing is more costly but is also a more sensitive means of 
testing.17 HPV testing has the advantage of detecting endocervical cancer in younger women 
better than simple cytology which might miss this diagnosis. The other cost-effective 
method for screening is visual inspection of the cervix with acetic acid (VIA). This method 
has been evaluated in multiple cross-sectional studies for its ability to detect HSIL and it has 
been shown that its sensitivity is quite close to that of cytology (62–80%), but its specificity 
is much lower (77–84%) when compared to the Pap smear. Adequate training and 
monitoring of this method of testing is needed to evaluate the quality of the visual test.18 
The current most affordable screening tool available in the public sector is thus the Pap 
smear – and hence needs to be utilised correctly, optimally and maximally. Since 2000, the 
National Government made no new recommendations or adjustments to the screening 
protocols. From the Sub-Saharan African statistics quoted, the incidence of invasive cancer 
of the cervix remains high, the diagnosis is often late in the majority of cases, and many 
patients have a poor response to treatment.19  
 
Cervical cancer screening recommendations differ from country to country and amongst the 
different organisations. As a comparison to South African recommendations (summarised in 
table 2b), table 2a summarises the different cervical cancer screening recommendations in 














Table 2a:  Cervical cancer screening recommendations from different professional 
organisations in the United States of America 45,46,47,48 
ORGANISATION AGE RECOMMENDED SCREENING 
TEST & FREQUENCY 
INITIATION DISCONTINUATION AGE 21 – 29 YRS AGE > 30 YRS 
 
ACS (American Cancer 
Society) / ASCCP 
(American Society for 
Colposcopy and Cervical 
Pathology) / ASCP 
(American Society for 






Pap test every 3 
years (preferred) 
 
One of these 
methods: 
▪ Co-testing (Pap 
test and HPV 
testing) every 5 
years (preferred) 
▪ Pap test every 3 
years 
ASCCP (American Society 
for Colposcopy and 
Cervical Pathology) / SGO 
(Society of Gynecologic 
Oncology) [2015 interim 
guidelines] 
21 N/A Can consider primary 
HPV testing every 3 
years for women age 
≥25 
Can consider primary 
HPV testing every 3 
years 
USPSTF (United States 
Preventive Services Task 
Force) [2018] 
21 65§ Pap test every 3 
years 
One of these 
methods: 
▪ Pap test every 3 
years 
▪ hrHPV testing 
alone every 5 
years 
▪ Co-testing (Pap 
test and HPV 
testing) every 5 
years 
ACOG (American College 
of Obstetricians and 
Gynecologist) [2016] 
21 65‡ One of these 
methods: 
▪ Pap test every 3 
years 
▪ Can consider 
primary HPV 
testing every 3 
years for 
women age ≥25 
One of these 
methods: 
▪ Co-testing (Pap 
test and HPV 
testing) every 5 
years (preferred) 
▪ Pap test every 3 
years 
▪ Can consider 
primary HPV 
testing every 3 
years for women 
age ≥25 
 
ACP (American College of 
Physicians) [2015] 
21 65§ Pap test every 3 
years 
One of these 
methods: 
▪ Pap test every 3 
years 
▪ Alternative: Co-
testing (Pap test 
and HPV testing) 
every 5 years 
¶ Regardless of the age of sexual initiation or other risk factors 
Δ For women with evidence of adequate negative prior screening (3 consecutive negative cytology results or 2 consecutive negative co-
tests within the previous 10 years, with the most recent test within the previous 5 years) and no history of CIN 2 or greater within the last 
20 years. Screening should not be resumed for any reason, even if a woman has a new sexual partner 
§ For women with evidence of adequate negative prior screening, specified as 3 consecutive negative cytology results or 2 consecutive 
negative co-tests within the previous 10 years, with the most recent test within the previous 5 years 
‡ For women with no history of CIN 2 or higher with evidence of prior adequate screening (3 or more negative cytology test results in a 




In South Africa, the South African Society of Obstetricians and Gynaecologists (SASOG) 
released a recent guideline on cervical screening in South Africa in 2015. This was developed 
by a team of professional experts from public health, virology, gynaecological oncology, 
anatomical pathology and cytology. It is the third guideline to be reviewed and published. It 
advises that in a low or high resource South African setting, screening should commence at 
the age of 25 years if the woman is HIV negative, otherwise, at the time of diagnosis if HIV 
positive. Screening should terminate at hysterectomy, provided that the tests were negative 
or at the age of 65 in high resource settings and the age of 55 years in the low resource 
setting. For those who are HIV positive, screening should never stop.20 Table 2b summarises 
these recommendations: 
Table 2b:  Primary Screening Guidelines as per SASOG 20 
From Table 2b, it is evident that an attempt to increase surveillance in the HIV positive 
population is underway since South Africa has one of the highest incidences of HIV, affecting 
13,1% of the population, as per the 2018 report by Stats SA (Statistics South Africa). 
Approximately one-fifth of women in their reproductive age (15–49 years) are HIV 
positive.21 Unlike other AIDS-defining neoplasms such as Kaposi's sarcoma and non-
Hodgkin's lymphoma, the development of cervical cancer is not solely dependent on 
immune compromise. HIV alters the natural history of HPV infection by causing a faster 
development to high grade and invasive lesions that are resistant to treatment, or which 
regress at a much slower rate. The more aggressive course is due to an interaction between 




At diagnosis of HIV positivity 
Age 25 
At diagnosis of HIV positivity 
End Screening Age 55 or hysterectomy 
(After previous negative tests) 
 
Age 65 or hysterectomy 
(After previous negative tests) 
Never End 
Screening 
HIV positive HIV positive 
Interval HPV 
Test 
10 years if HIV negative or unknown 
5 years if HIV positive 
5 years if HIV negative or unknown 
3 years if HIV positive 
Interval 
Cytology 
5 years if HIV negative or unknown 
3 years if HIV positive 
3 years if HIV negative or unknown 
Yearly if HIV positive 
Timing Ten-yearly: At ages 25, 35, 45, 55 
Five-yearly: Also at ages 30, 40, 50 
Three-yearly: At ages 25, 28, 30, 33, 
36, 40, 43, 46, etc 
Five-yearly: Also at ages 30, 40, 50 
Three-yearly: At ages 25, 28, 30, 33, 
36, 40, 43, 46, etc 
Yearly: each year 
Follow-up After single abnormal screening test or 
after treatment: 
- HIV negative and 
<35years: 5 yearly until 
normal 
- HIV positive or >35years: 
yearly until normal 
Back to SCREEN when normal 
Treat after second abnormal test 
After single abnormal screening test or 
after treatment: 
- HIV negative and 
<35years: yearly until 
normal 
- HIV positive or >35years: 
yearly until normal 
Back to SCREEN when normal 
Treat after second abnormal test 
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HPV and HIV viral proteins. HIV enhances the effectiveness of HPV proteins, resulting in a 
change in the molecular pathway and perhaps, to cell cycle disruption.22  
 
The detection of HPV infection increases quite rapidly within the first years after HIV 
seroconversion. This raises the hypothesis that mucosal immune dysfunction occurring at an 
early stage of HIV infection might influence HPV-related diseases. Wang et al. showed that 
among HIV seroconverters, HPV infection prevalence doubled at and after seroconversion, 
compared to before seroconverting. HIV seroconversion was associated with newly 
detected HPV infection and increased risk of low-grade cytological abnormalities.23 
In Africa, over the past few years, the incidence of cervical cancer has increased among 
younger women, driving the WHO to warn low-resource areas that global cervical cancer 
deaths will increase to 460 000 by the year 2040 – and that low- and middle-income 
countries (LMICs) will have the greatest relative increase.24 Furthermore, it has been noted 
that younger patients with cervical cancer have worse clinical and overall survival 
outcomes.25,26 Patient age also seems to be an independent determining factor for early 
recurrence of cervical cancer.27 Characteristics like poor tumour differentiation and lymph 
node metastasis in these younger patients may collectively contribute to early recurrence of 
cervical cancer in this patient population subset.28 
Approximately 7 out of 10 women will remain alive five years after diagnosis, in first world 
countries compared to many developing countries, who have an overall survival rate of less 
than 40%.29  
One of the essential factors in determining the treatment and prognosis of cervical cancer is 
the staging of the disease. Other factors include the age of the patient, the HIV status, 
parametrial involvement, tumour histology and general health of the patient.30 Table 3 
provides a summary of the overall five-year survival rates according to the stage of the 
disease, by FIGO (International Federation of Gynaecology and Obstetrics).31 
Table 3 : Percentage of women alive after five years, inclusive of all age groups : 1999 to 
2001 (as per FIGO statistics) 











This study gathered recent institutional statistics to gain better insight into the institution's 




Single institution study 
The research and data collection for the study took place at the Groote Schuur Hospital 
Gynaecological Oncology Unit (LE33), in Cape Town, Western Cape, South Africa.  
 
Time 
The study analysis was from 1 January 2003 until 31 December 2012 and compared to the 
previous decade (1 January 1993 until 31 December 2002). 
 
Study design  
The study conducted a retrospective audit of files from 1 January 1993 until 31 December 
2012 and appropriate data extracted. Survival and disease-free outcomes at five years, as 
well as time to recurrence, was assessed, together with other demographics as dictated by 
the study outcomes. 
 
Study population  
The inclusion criteria were non-pregnant female patients, aged 40 years and younger at the 
time of registration with the Groote Schuur Hospital (GSH) Oncology Unit (LE 33). These 
patients had to have a histologically confirmed cervical cancer. Only squamous cell 
carcinoma, adenosquamous carcinoma and adenocarcinoma histology were included. 
Patients must have attended at the LE 33 unit on or from 1 January 1993 until and including 
31 December 2012. 
 
Patients excluded from the study were those women who were pregnant upon entry into 
the unit, those aged 41 years and older and those patients diagnosed with histology other 
than squamous, adenosquamous and adenocarcinoma. Patients receiving treatment at any 
other oncology unit in the Western Cape or South Africa were excluded from this study.  
 
Study aim 
This study aimed to compare trends in the 5-year survival outcomes for cervical cancer 
(adenocarcinoma, adenosquamous carcinoma and squamous cell carcinoma) in women 40 
years and younger, using data from the Gynaecological Oncology Unit (LE33) at Groote 
Schuur Hospital from 1 January 2003 until 31 December 2012, and to compare this data to 





This study analysed three primary outcomes: five-year overall survival, five-year disease 
outcome and the time to recurrence. 
 
The secondary outcomes in this retrospective audit assessed the clinical and pathological 
characteristics of patients diagnosed with cervical cancer at 40 years or younger. It also 
evaluated the influence that HIV status has on cervical cancer. Clinical features that were 
analysed were age at entry into the unit (age at diagnosis), stage at diagnosis, HIV status, 
haemoglobin (Hb) level at presentation, tumour size clinically, presence of hydronephrosis, 
parametrial involvement and treatments offered. 
 
The above outcomes studied for each of the ten years (1 January 1993 – 31 December 2002 




The database used for the collection was Microsoft Excel 2016. An electronic data capturing 
device (Samsung Tab A 10,1) aided in capturing data electronically. The author's laptop 
(Acer Aspire V) then received this data. All data was backed-up to an external hard-drive. 
The author printed a hard-copy of the captured data, carefully filed, analysed and stored it 
in a locked cupboard. 
 
The author ensured the security and confidentiality of the data at all times in the following 
ways: 
- The anonymity of patients included in the study was maintained by identifying 
patients by a specially allocated number, rather than by name or folder number 
during the data collection and capturing on the datasheet  
- Documents are all password protected 
- All changes to the data capturing document saved as new versions and all devices 
had up-to-date virus protection. 
- No data was sent via or uploaded to the internet. 
- Secure and private electronic versions of write-ups (including the concept note, the 
research proposal, the university forms for submission and the write up of the article 
post data analysis) were used and sent via email to communicate to supervisors, due 




Files containing patients’ one-page summaries (‘registration forms’)  completed by the 
multidisciplinary team at the Combined Assessment Clinic (CAC) at GSH LE 33 unit, during 
the period 1 January 1993 until 31 December 2012, and who met the inclusion criteria of the 
study, were collected and analysed for data pertaining to the aims of this study. The data 
extracted from these folders assisted with comparison and supplementation to the 
information on the existing database at LE33 Gynae Oncology. Data was then analysed to 
obtain relevant information to meet the primary and secondary study outcomes.  
 
 
Ethical clearance and consent 
The database approval number is HREC REF 344/2011. The University of Cape Town (UCT) 
HREC granted ethical approval for this study – HREC REF 143/2020. 
 
The Chief Executive Officer (CEO) of GSH granted institutional consent (Appendix 1). 
Permission to conduct my study at the gynaecological oncology unit LE33 and to allow me to 




The budget, inclusive of travel expenses, data and internet, stationery, printing, postage and 
biostatistical analysis, was all self-funded. 
 
Clarity and study definitions 
A glossary of the abbreviations used in this article appears at the end of the article, listed 
alphabetically. For clarity and universality, it is important to note the following in the 
context of this study: 
• The staging of cervical cancer adopted in this study is the clinical FIGO Staging 
revised in 2009.  
• The guidelines and protocols practised at Groote Schuur Hospital, are per the 
National Cancer Institute (NCI) guidelines. 
• 'Early-stage cancer' or 'early cervical disease' refers to stage 1 and 2 cervical cancer, 
and stage 3 and 4, will be termed 'late-stage cancer/disease' for the scope and 
comparison in this study. 
• For ease of comparison, the period 1 January 1993 through to 31 December 2002, 
will be referred to as ‘decade A’ and the following ten years (1 January 2003 through 
to 31 December 2012), will be referred to as ‘decade B’, to avoid any confusion. 
15 
 
• The term ‘young women’ refers to those patients 40 years and younger, while those 
women referred to as being in the ‘older’ age group incorporates those patients 41 
years and older. 
• Women grouped and termed as ‘NP’ (not positive), are those patients who were 
tested and found to be HIV negative as well as those patients who were never tested 























After collecting, supplementing and cross-checking the data, the data was then anonymised 
and cleaned - keeping the primary and secondary outcomes in mind. An actuary then 
analysed the data. Crude Kaplan-Meier curves were drawn for the primary outcomes and 
tested for statistical significance using Log Rank tests. Secondary outcomes were analysed 
through univariate analyses and tested for statistical significance using p-values. 
 
Tables and graphs show the results and observations to better understand and view 
comparisons between the two decades under study. 
 
Results 
Flow of patients in the study 
As per Figure 1, in decade A, there were a total of 1451 patients that were in the cervical 
cancer database, of which 1160 patients (80%) did not fulfil the age criteria. This left 291 
patients (20%) that were 40 years and younger during this decade. Excluded patients 
comprised ten pregnant women (3%) and a further eight (3%), based on the histology 
exclusion criteria. The median age at diagnosis, in those 40 years and younger during decade 
A was 36 years.  
 
There were a total of 1695 women that entered the unit diagnosed with cervical cancer 
during decade B. In this decade, 1350 patients (80%) were 41 years and older. After applying 
the inclusion criteria, 310 women (18%) were left for analysis in this decade, with a median 
age of 35 years.  
 











Figure 1 : Flow of patients in the study 










For ease of comparison and to obtain better clarity of the population subset under study, 
the author decided to report on the secondary outcome results first and then those of the 
primary outcomes. 
 
SECONDARY OUTCOMES  
Age at entry into the unit  
Age at entry into the unit was taken as a measure of 'age at diagnosis' when the patient 
entered the LE 33 unit at GSH, for this study. Trends were analysed to see the distribution of 
patients.  
 
Table 4a, Table 4b and Figure 2 show the spread of the patients included in the study for 
each decade, according to the age distribution, HIV status, histology and stage of cancer at 
diagnosis. 
 
Young women (those 40 years and younger), accounted for approximately 20% of all the 
patients on the database for each decade. Of this, 49 patients (18%) and 51 patients (16%) 
were under the age of 30 years in decade A and B, respectively. The highest incidence, in 
each decade, was in patients between age 31 to 40 years. This group will likely not benefit 
from the South African cervical cancer screening guidelines implemented. There is no 





Table 4a : Distribution of patients by age group, according to HIV status, histology and 






Table 4b : Distribution of patients by age group, according to HIV status, histology and 






  Decade A (n = 273) 
Age  N HIV Status Cervical Cancer Histology Stage of Cancer 
    POS NEG NS Adenocarcinoma Squamous Adenosquamous ia ib ii iii&iv 
0-20 0 0 0 0 0 0 0 0 0 0 0 
21-30 49 5 6 38 2 46 1 4 11 7 27 
31-40 224 7 32 185 20 185 19 24 65 46 89 
Total 273 12 38 223 22 231  20 28 76 53 116 
% of 
total 
 4% 14% 82% 8% 85% 7% 10% 28% 19% 42% 
  Decade B (n = 310) 
Age N HIV Status Cervical Cancer Histology Stage of Cancer 
    POS NEG NS Adenocarcinoma Squamous Adenosquamous ia ib ii iii&iv 
0-20 0 0 0 0 0 0 0 0 0 0 0 
21-30 51 23 28 0 3 46 2 11 10 28 2 
31-40 259 79 156 24 17 235 7 31 51 162 15 
Total 310 102 184 24 20 281 9 42 61 190 17 
% of 
total 
 33% 59% 8% 6% 91% 3% 14% 20% 61% 5% 
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Histology    
The histological distribution of cervical cancer during each decade (Figure 3) has remained 
similar: 85% of patients (231) during decade A diagnosed with squamous cell carcinoma 
while 90% of patients (281) during decade B had the same histological type. 
Adenocarcinoma was present in 8% (22 patients) of those young women in decade A and 6% 
(20 patients) of those in decade B. The incidence of adenosquamous histology has 
decreased only slightly from 7% (20 patients) in decade A to 3% (9 patients) in the more 
recent decade B. No change in the trend of histological distribution occurred over the two 




































PROPORTION OF YOUNG WOMEN DIAGNOSED WITH CERVIAL CANCER
(20%) (55%) (25%) 
(20%) (56%) (24%) 
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There was no routine documentation done of patient's HIV status on the cervical cancer 
database or the LE 33 Combined Assessment Clinic registration form, especially for the first 
ten years under study. Attempts at obtaining this information physically or electronically via 
the NHLS (National Health Laboratory Service), the NHLS TrakCare website or the DISA 
Website proved unsuccessful due to the period under study going back as far as it did. 
Figure 4 clearly shows that during decade A, the recording of patients' HIV status was sparse 
and hence, more than 80 % of patients in this decade fell in the 'not specified' group. Only 
4% of patients (12) were documented as being HIV positive, while 14% (38 patients) were 
negative. Although HIV counselling and testing began formally in 2011 on the government 
roll-out initiative, Groote Schuur Hospital did start a rigorous recording of patient's HIV 
status before then – notable in the second ten-year period under study. This shift in 
awareness and testing resulted in the marked improvement seen in Figure 4 during decade 
B, where 92% (286) of patients had their HIV status documented and recorded. In this 
decade, a third of patients (102) were HIV positive, and 59% (184 patients) documented as 
HIV negative. 
 
Further analysis with regards to whether HIV positive patients were on ARV (antiretroviral) 








































diagnosed at the time of cervical cancer diagnosis were not reviewed or assessed during this 
study. 
 





The stage at entry into the unit 
This was taken as a measure of ‘stage at diagnosis’. Figure 5 indicates that each of the 
decades differs with regards to stage at diagnosis. During decade A, 157 patients (58%) 
presented with early-stage disease – comprising of 66% (104) of stage 1 patients and 34% 
(53) of stage 2 patients. In decade A, 116 patients (42%) presented with late-stage cancer. 
Decade B's trend shows that 293 patients (95%) presented with early-stage cancer – 33% 
(103) stage 1 and 62% (190) stage 2; while only 17 (5%) patients had late-stage disease. This 
could be an indication that a fair amount of younger women report abnormal vaginal 
bleeding and discharge, associated with cervical cancer while some had their diagnosis 
made during screening. 
































*HIV NS (not specified) – inclusive of patients not tested and those with undocumented results   
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The proportion of all early-stage cancers in decade A was not significantly similar to that in 
decade B (p<0,0001). Out of the early-stage cervical cancer cohort, stage 2 proportion is not 
significantly static between the two decades (p<0,0001). Hence, there were more patients 
diagnosed with stage 2 cervical cancer in decade B than in A. The reason for this finding 
could be that patients may have presented with probably, bigger tumours with parametrial 
involvement. It was difficult to correlate this with HIV status, as HIV testing and 












Stage ia Stage ib Stage ii Stage iii&iv
Decade A
(n = 273)
28 76 53 116
Decade B
(n = 310)


















DISTRIBUTION OF YOUNG WOMEN DIAGNOSED WITH CERVICAL CANCER 
ACCORDING TO STAGE
(43%) (19%) (28%) (10%) 
(5%) (61%) (20%) (14%) 
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Initial Haemoglobin (Hb) at presentation 
 
The patient's Hb at presentation to LE 33 unit, together with its trends, were analysed. This 
study did not analyse further information about whether patients had received a blood 
transfusion or intravenous or oral iron supplementation before being seen at the unit. Only 
one patient during decade A had no initial Hb level documented. 
 
Figure 6 shows that during both decades, the majority of patients have fairly good Hb’s 
(8g/dL and above) at entry into the LE 33 unit, independent of HIV status. Low Hb level at 
presentation could be related to the severity of the bleed and the chronic nature of cancer. 
 
The Hb level at initial presentation has shown not to have deteriorated with the passing 
decades, despite the rising HIV awareness and statistics. Information on the administration 
of blood or iron transfusion or supplementation before the initial LE 33 unit presentation 
would have been helpful to obtain a better clinical picture of this parameter and its effect 
on treatment and survival outcomes.  
 
Figure 6 : Distribution of young women diagnosed with cervical cancer by Hb level, 






















NUMBER OF YOUNG WOMEN BY HB LEVEL, ACCORDING TO HIV STATUS 
HIV POS HIV NP
Decade A Decade B Decade A Decade B Decade A Decade B Decade A Decade B
HIV POS 0 4 3 6 4 34 5 58
HIV NP 7 5 8 13 65 42 180 148
≤6 g/dL 6,1-8 g/dL 8,1-10 g/dL >10 g/dL
(HIV not positive, inclusive of HIV negative and HIV ‘not specified’) 
Decade A n = 272 (12 HIV POS and 260 HIV NP), Decade B n = 310 (102 HIV POS and 208 HIV NP) 
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Cancer stage: tumour size, hydronephrosis and parametrial involvement 
 
Information regarding tumour size, hydronephrosis and parametrial invasion were collected 
and analysed to gain further insight into cancer ‘aggression’. 
    
Tumour size in almost all patients with cervical cancer was measured clinically. Therefore, 
measurements are mainly subjective. Table 5 reviews tumour size according to early-stage 
cancer for each decade. Of all the early-stage cancers (stage 1a, 1b and 2) during decade A, 
104 patients (66%) with stage 1 (1a and 1b) cancers, had presented with tumours 4cm and 
less in size. This was the case for only 99 patients (34%) of the same subset in decade B. The 
proportion of stage 1 cancers with tumours 4cm and less is significantly different between 
the decades (p<0,0001). The proportion of women with tumours 0 – 2cm in size in decade A 
is significantly less than the equivalent group in decade B (p<0,001). For tumours 2 – 4cm in 
size, there was a larger proportion of patients during decade B than during decade A 
(p<0,001). Approximately 5% of patients (8) in decade A with tumours more than 4cm had 
stage 2 cervical cancer and 10% (24) of stage 2 cancer patients in decade B had tumours 
more than 4cm; however, this increasing trend is not statistically significant (p=0,22). 
 
 
Figure 7 graphically depicts that the majority of patients, whether HIV positive or not, 
present with an average tumour size of 2 to 4 cm on clinical examination, in both decades A 
and B. Due to the small number of HIV patients during decade A, reliable comparisons could 
not be made. During decade B, for tumours 0 – 4 cm in size, HIV status is shown not to be 
significantly independent of tumour size (p=0,02). The sample cohort for tumour size larger 
















 Decade A (n = 157) Decade B (n = 293) 
Tumour 
Size 
Stage of Cancer Stage of Cancer 
  ia ib ii Ia ib Ii 
0-2 cm 28 54 7 42 44 5 
2,1-4 cm 0 22 38 0 13 161 
>4 cm 0 0 8 0 4 24 
Total 28 76 53 42 61 190 






Figure 7 : Distribution of tumour size in young women diagnosed with cervical cancer, 
according to HIV status 
 
 













HIV NP 89 57 162 125 10 26


















DISTRIBUTION OF TUMOUR SIZE IN YOUNG WOMEN DIAGNOSED WITH 
CERVICAL CANCER, ACCORDING TO HIV STATUS
Decade A n = 273 (12 HIV POS and 261 HIV NP), Decade B n = 310 (102 HIV POS and 208 HIV NP) 
(HIV not positive, inclusive of HIV negative and HIV ‘not specified’) 
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Table 6a shows that the proportion of patients with hydronephrosis and late-stage cancer, 
during decade A and B, do not differ significantly (p=0,67). From Table 6b, it is evident that 
patients with late-stage cancer without hydronephrosis have similar trends between the 
decades: in decade A, a mean survival of 30 months (median 16 months) for stage 3b and 6 
months (median 4,5 months) for stage 4, while in decade B the same population subset has 
a mean survival of 25 months (median 15 months) and 6 months (median 4 months) 
respectively. A sub-analysis of mean survival in patients with stage 3b disease indicated that 
the presence of hydronephrosis (whether unilateral or bilateral) had remained unchanged 
from decade A (mean 13 months) to decade B (mean 12 months). The median survival 
increased from 4,5 months during decade A to 9 months in decade B. Stage 4 cancer 
patients with hydronephrosis showed the biggest difference, where their mean survival 
drops from 8 months (median 4 months) in decade A to 3 months (median 2 months) in 




Table 6a : Distribution of the number of young women with hydronephrosis, according to 
















 Decade A (n = 114) Decade B (n = 152) 
Hydronephrosis Stage of Cancer Stage of Cancer 
  iiib iv iiib Iv 
NIL 51 15 76 8 
UNI 26 5 33 5 
BIL 9 8 26 4 
Total 86 28 135 17 
% of total 75% 25% 89% 11% 
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Table 6b : Mean survival in months of young women with and without hydronephrosis, 









Table 7a shows that during decade A and B, the proportion of patients with unilateral 
parametrial involvement has significantly decreased (p<0,0001), while those with bilateral 
(p=0,02) and pelvic sidewall invasion have significantly increased (p=0,04). Table 7b shows 
that the mean overall survival of patients with parametrial involvement (unilateral and 
bilateral) as well as those patients with pelvic sidewall invasion have not changed 




Table 7a : Distribution of the number of young women with parametrial involvement, 











 Decade A (n = 114) Decade B (n = 152) 
Hydronephrosis Stage of Cancer Stage of Cancer 
  iiib iv iiib Iv 
ABSENT 30 6 25 6 
PRESENT 13 8 12 3 
 Decade A (n = 135) Decade B (n = 189) 
Involvement Stage of Cancer Stage of Cancer 
  iib iii iib Iii 
NIL 0 0 0 1 
UNI 33 18 20 15 
BIL 15 64 34 101 
PSW 0 5 0 18 
Total 48 87 54 135 
% of total 36% 64% 29% 71% 
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Table 7b : Mean survival in months of young women with and without parametrial 
involvement, according to late stages of cervical cancer 
 
 
 Decade A (n = 135) Decade B (n = 189) 
Involvement Stage of Cancer Stage of Cancer 
  iib iii iib Iii 
NIL - - - 60 
UNI 45 34 43 24 
BIL 34 18 31 12 




Young women who met the inclusion criteria for the study were analysed and compared 
according to the treatments they received. The guidelines and protocols practised at Groote 
Schuur Hospital, are per the National Cancer Institute (NCI) guidelines. Treatment of cervical 
cancer is stage-dependent and therapies were grouped into six categories, as follows (the 
corresponding group depicted in Figure 8 shown in parenthesis below): 
1. surgery with or without EBRT (external beam radiotherapy), adjuvant vault 
brachytherapy or adjuvant EBRT and vault brachytherapy (group 1) 
2. EBRT followed by brachytherapy (group 2) 
3. chemotherapy only (group 3)  
4. concurrent chemotherapy (group 4)  
5. vault brachytherapy or EBRT alone (group 5) 
6. palliative care (group 6) 
 
The data was incomplete for only one patient in decade A. As depicted in Figure 8, during 
decade A the majority of patients received treatment groups 1 or 2. Concurrent chemo-
radiotherapy has shown to improve survival in patients with locally advanced cervical 
cancer.32,33 Following the evidence from the literature, the majority of patients in decade B 
received concurrent chemotherapy (87 patients in treatment group 4) or surgery (91 
patients in treatment group 1), followed then by radiotherapy (50 patients in treatment 
group 2). Only in exceptional cases, surgery after chemotherapy occurred (e.g. young 
women with cervical cancer diagnosed in pregnancy). The graph in Figure 8 demonstrates 
this evident shift in management from 1999 onwards where the implementation of a 
combination of radiotherapy and chemotherapy began to manage patients in decade B, in 
contrast to decade A where young women with cervical cancer received mainly 
29 
 
radiotherapy without chemotherapy. In decade A, there is a spread of treatments received, 
but given the small overall HIV positive subset, there are no evident material trends. As 
expected, in decade B (given that in practice treatment is not HIV-dependent), the data 
shows no clear relationship between HIV status and treatment type. 
 
 
Figure 8 : Distribution of different types of treatment received in young women diagnosed 
with cervical cancer, according to HIV status 
 
 
 HIV POS  HIV NP (HIV not positive, inclusive of HIV negative and HIV ‘not specified’) 
 
 
Figure 9 shows that since cervical cancer treatment is stage-dependent, the majority of 
stage 1 disease in both decades received surgery with or without radiotherapy (treatment 
group 1). The proportion of stage 2 cancers that received radiotherapy significantly 
increased from decade A to B (p<0,001). A similar significant increase occurred for those 










































HIV NP 100 60 68 24 5 1 38 80 22 24 27 19


















DISTRIBUTION OF TREATMENT TYPES RECEIVED AMONG YOUNG WOMEN WITH 
CERVICAL CANCER BY HIV STATUS
DECADE A : n = 272 (1) - surgery with or without EBRT, adjuvant vault brachytherapy or adjuvant EBRT and vault brachytherapy
DECADE B : n = 310 (2) - EBRT followed by brachytherapy (3) - chemotherapy only
(4) - concurrent chemotherapy (5) - vault brachytherapy or EBRT alone
(6) - palliative care
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Figure 9 : Distribution of different types of treatment received in young women diagnosed 





















































ia 28 42 0 0 0 0 0 0 0 0 0 0
ib 68 47 3 0 0 0 3 10 1 0 1 4
ii 3 1 33 50 0 1 14 75 1 35 2 28



















DISTRIBUTION OF TYPES OF TREATMENT RECEIVED AMONG YOUNG WOMEN 
WITH CERVICAL CANCER, ACCORDING TO CANCER STAGE
DECADE A : n = 272 (1) - surgery with or without EBRT, adjuvant vault brachytherapy or adjuvant EBRT and vault brachytherapy
DECADE B : n = 310 (2) - EBRT followed by brachytherapy (3) - chemotherapy only
(4) - concurrent chemotherapy (5) - vault brachytherapy or EBRT alone






5-year overall survival 
In this study, six categories of survival curves were drawn up and analysed to compare 
decade trends.  
 
The first curve analysed was survival according to age groups, comparing young women with 
cervical cancer (those 40 years and younger) with those women 41 – 60 years of age in 
decade A and decade B (Figure 10). Figure 10 illustrates that during decade A, the older age 
group had an overall survival trend very similar to that of the younger age group – no 
statistical difference was observed (p=0,31). However, in decade B, the younger and older 
age groups initially follow a similar survival trend until approximately 20 months, where 
after the younger population shows a better probability of survival than the older age 
group. However, once again, this observation is not statistically significant (p=0,9). Looking 
more closely at the subset of patients included for this study (those 0 – 40 years), the overall 
survival of this younger subset of women during decade A was only marginally better but 
not statistically significant over earlier durations than that during decade B (p=0,6). Hence, 
there was no statistically significant difference in overall survival in younger women (0 – 40 
years) from decade A to decade B. 
 
 
























KAPLAN-MEIER SURVIVAL CURVE SHOWING OVERALL 
SURVIVAL BY AGE
Decade A - young (n=273) Decade A - old (n=780)
Decade B - young (n=310) Decade B - old (n=942)
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The second survival curve analysed, evaluated the probability of survival in those patients 
meeting the inclusion criteria of the study that were HIV positive versus those women who 
were HIV negative and those unspecified (referred to as ‘NP’ – not positive), in each decade 
(Figure 11). Data were analysed and compared to see the trend, even though there were 
markedly fewer HIV status recordings in decade A. 
 
Figure 11 shows that in both decades A and B, HIV positive patients had a slightly worse 
overall probability of survival than those diagnosed as HIV NP (p=0,73 for decade A and 
p=0,88 for decade B). It can also be noted that conditional on 3-year survival, HIV positive 
patients in decade A (albeit few) had subsequently better 5-year survival outcomes (very 
similar to those HIV NP patients in both decade A and B) compared to those in decade B, 
however, this proved not to be statistically significant (p=0,29). Therefore, there is not 
enough convincing evidence to show a difference in overall survival outcomes based on HIV 
status. 
 
The actual mean survival in months in those HIV positive and NP women has decreased 
from decade A to decade B, as depicted in Table 8. Patients with a NP status have better 
mean survival than those that are status positive during both decades.  
 

























KAPLAN-MEIER SURVIVAL CURVE SHOWING OVERALL 
SURVIVAL IN YOUNG WOMEN BY HIV STATUS
Decade A - HIV POS (n=12) Decade A - HIV NP (n=261)
Decade B - HIV POS (n=102) Decade B - HIV NP (n=208)
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Table 8 : Mean survival in months of young women diagnosed with cervical cancer, 








Figures 12a and 12b show the Kaplan-Meier curves comparing the stage at diagnosis (taken 
from the stage at entry into the unit) in each decade for those women meeting the inclusion 
criteria for the study. 
Across all durations, cervical cancer stage 1a and 1b have the best probability of survival. 
Decade B's stage 1b patients appear to show an improvement in survival when compared to 
the equivalent decade A stage 1b patients' survival; however, this proved not to be 
statistically significant (p=0,94). No significant difference in overall survival among women 
with stage 2 cancer during decade A and B was noted (p=0,99). Late-stage cervical cancer 
(stage 3 and 4), has the worst survival probability for both decade A and B, with no 
significant difference in change of trend pattern observed from decade A to decade B 
(p=0,99). 
 
Table 9 shows that there has been an improvement in mean survival time from decade A to 
decade B in stage 1a and 1b cervical cancer. There is a decrease in the mean survival of 
approximately 50% from decade A to decade B in those women with stage 2 cervical cancer. 
Late-stage cancer's mean survival has also decreased from 24 months in decade A to 3 
months in decade B. This shows a deterioration in mean survival in patients with stage 2 and 














HIV POS 35 26 
HIV NP 37 29 
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Figure 12a : Probability of survival in young women with cervical cancer, according to 





Figure 12b : Probability of survival in young women with cervical cancer, according to 























DECADE A: KAPLAN-MEIER SURVIVAL CURVE SHOWING 
OVERALL SURVIVAL IN YOUNG WOMEN BY CERVICAL 
CANCER STAGE
Decade A - stage ia (n=28) Decade A - stage ib (n=76)





















DECADE B: KAPLAN-MEIER SURVIVAL CURVE SHOWING 
OVERALL SURVIVAL BY CERVICAL CANCER STAGE IN YOUNG 
WOMEN
Decade B - stage ia (n=42) Decade B - stage ib (n=61)
Decade B - stage ii (n=190) Decade B = stage iii&iv (n=17)
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Table 9 : Mean survival in months of young women diagnosed with cervical cancer, 








Treatment received was analysed according to overall survival per HIV status, for each 
decade (Figures 13a and 13b). For this analysis, treatment was subdivided into four 
categories for ease of comparison, as follows – corresponding groups indicated in 
parentheses: 
1. surgery with or without EBRT (external beam radiotherapy), adjuvant vault 
brachytherapy or adjuvant EBRT and vault brachytherapy (group W) 
2. EBRT and intracavitary brachytherapy; chemotherapy only; vault brachytherapy or 
EBRT alone (group X) 
3. concurrent chemotherapy (group Y)  
4. palliative care (group Z) 
 
 
The HIV positive subset of decade A has immaterial exposures for treatment groups W, Y 
and Z. This results in the marked discontinuities in the graph and makes comparisons to this 
not credible.  
 
During decade B, young women receiving surgery with or without radiotherapy (treatment 
group W), independent of HIV status, had favourable five-year overall survival outcomes 
relative to the other treatment groups. Those patients in this decade that were HIV positive, 
however, can be noted to have only a marginally worse survival outcome when compared to 
those with a negative status, across all treatment groups (p>0,05). 
 
An improvement in survival outcomes across all durations over the five-years can be noted 
in decade B relative to decade A for treatment groups W and Y for HIV NP patients (p<0,05). 
 
Those patients receiving treatment group Z or group X can be seen in decade B to be having 






ia 40 59 
ib 47 56 
ii 48 21 
iii&iv 24 3 
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Figure 13a : Probability of survival in young women with cervical cancer, according to 

























DECADE A: KAPLAN-MEIER SURVIVAL CURVE SHOWING 
OVERALL SURVIVAL BY CERVICAL CANCER TREATMENT 
TYPE IN YOUNG WOMEN WITH A HIV POSITIVE STATUS





















DECADE A: KAPLAN-MEIER SURVIVAL CURVE SHOWING 
OVERALL SURVIVAL BY CERVICAL CANCER TREATMENT 
TYPE IN YOUNG WOMEN WITH A HIV NP STATUS
W X Y Z
KEY: 
W - surgery with or without EBRT (external beam radiotherapy), adjuvant vault brachytherapy or adjuvant EBRT and vault 
brachytherapy  
X - EBRT and intracavitary brachytherapy; chemotherapy only; vault brachytherapy or EBRT alone  
Y - concurrent chemotherapy  




Figure 13b : Probability of survival in young women with cervical cancer, according to 
























DECADE B: KAPLAN-MEIER SURVIVAL CURVE SHOWING 
OVERALL SURVIVAL BY CERVICAL CANCER TREATMENT TYPE 
IN YOUNG WOMEN WITH A HIV NP STATUS





















DECADE B: KAPLAN-MEIER SURVIVAL CURVE SHOWING 
OVERALL SURVIVAL BY CERVICAL CANCER TREATMENT 
TYPE IN YOUNG WOMEN WITH A HIV POSITIVE STATUS
W X Y Z
KEY: 
W - surgery with or without EBRT (external beam radiotherapy), adjuvant vault brachytherapy or adjuvant EBRT and vault 
brachytherapy  
X - EBRT and intracavitary brachytherapy; chemotherapy only; vault brachytherapy or EBRT alone  
Y - concurrent chemotherapy  




Despite being the second most common histological type (after squamous cell carcinoma) in 
this study, adenocarcinoma of the cervix is the histological subtype with the best survival 
probability according to the curves depicted in Figures 14a and 14b, during both decade A 
and B respectively. The 5-year prognosis in patients with adenocarcinoma as a histological 
type is usually poorer than those with squamous histology. However, despite the small 
cohort, from Figure 14a and 14b it appears as though patients with adenocarcinoma fared 
better in this study than those with squamous cell carcinoma tumours. However, the effect 
of histology appears to converge with duration. For each decade, there is no statistically 
significant difference observed between overall survival probability between the different 
histological types of cervical cancer (p= 0,9 for decade A and p=0,62 for decade B). When 
comparing the trends from decade A to decade B for each histological type, no statistically 
significant difference in overall survival is observed (p=0,47, p=0,14 and p=0,57 respectively 































DECADE A: KAPLAN-MEIER SURVIVAL CURVES  
SHOWING OVERALL SURVIVAL BY HISTOLOGY FOR 




Figure 14b : Probability of survival in young women with cervical cancer, according to 





Figures 15a and 15b depict curves for the probability of disease-free survival, according to 
the different early stages of cervical cancer in decade A and decade B, respectively. 
There is very minimal change in the trends of disease-free survival from decade A to decade 
B. There is no statistically significant difference observed between the decade comparisons 






























DECADE B: KAPLAN-MEIER SURVIVAL CURVES  
SHOWING OVERALL SURVIVAL BY HISTOLOGY FOR 




Figure 15a : Probability of disease-free survival in young women, according to early stages 




Figure 15b : Probability of disease-free survival in young women, according to early stages 






























DECADE A: KAPLAN-MEIER SURVIVAL CURVE SHOWING DISEASE-FREE 
INTERVAL IN YOUNG WOMEN BY EARLY STAGES OF CERVICAL CANCER




























DECADE B: KAPLAN-MEIER SURVIVAL CURVE SHOWING DISEASE-FREE 
INTERVAL IN YOUNG WOMEN BY EARLY STAGES OF CERVICAL CANCER
Decade B - stage ia (n=42) Decade B - stage ib (n=61) Decade B - stage ii (n=190)
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5-year disease outcome 
As a parameter of an assessment of treatment outcome, the 5-year (60 months) disease 
status of young women diagnosed with cervical cancer was analysed. 
 
In Figure 16, the proportion of those patients that are alive with no evidence of disease 
(NED) in decade A is 31% (84 patients) and 38% (117 patients) in decade B, showing no 
significant difference in change of trend between the decades under study (p=0,08). The 
proportion of patients who suffered cancer-related deaths at five years in decade A and B 
stayed static at 55% (150 patients in decade A and 171 in decade B). The study data do not 
show significant evidence that survival outcome does not differ between decades (p=0,3). 
Those patients that died due to other causes and that were lost to follow up were in the 









Figure 17 depicts that a higher proportion of young women with early-stage cancer (stage 
1a, stage 1b or stage 2) were alive with no evidence of disease at five years in decade B than 
in the prior decade (p=0,01). However, late-stage cancer in decade B had no survivors at 5-
year follow up, compared to decade A. Death due to cancer in these young women are 
Decade A : n= 273 Decade B : n= 310
























DISTRIBUTION OF 5 YEAR DISEASE OUTCOMES 













noted to be markedly less with those with stage 1b, stage 3 and stage 4 cancer, during 
decade B than during decade A (p<0,00001). There is an increase in patients with stage 2 
cancer dying from the disease in decade B (81% - 139 patients) when evaluated in contrast 
to decade A (20% - 30 patients), p<0,0001. This implies that more stage 2 cancer patients 
are dying from the disease in the more recent decade than the prior (p<0,01). As a result of 
clinical staging, some of the stage 2 patients could have been more advanced than clinically 
assessed at the first visit. The new 2018 revised FIGO staging for cervical cancer 
incorporates the use of CT (computed tomography) scans and MRI (magnetic resonance 
imaging), a move that could assist in improved staging and treatment outcomes. Type of 
treatments offered and received and whether treatment course was completed, would be 
other factors to consider as possible explanations for this finding. The proportion of patients 
lost to follow up across all stages of the disease, is noted to be comparable in decade A and 
B, signifying no better patient attendance with advancing decades. 
 
 
Figure 17 : Distribution of 5-year disease outcomes among young women diagnosed with 





Five-year disease outcome in young women with cervical cancer, according to HIV status, 
was carefully evaluated and compared between the decades under study (Figure 18). 
Although very few patients in decade A had HIV statuses documented, a comparison of 

























LFU Lost 6 2 3 1 1 3 8 0
Dead OTH 4 2 10 2 4 11 3 0
Dead CAN 1 1 25 14 30 139 94 17
Alive CAN 0 0 0 1 0 0 0 0























DISTRIBUTION OF 5 YEAR DISEASE OUTCOMES AMONG YOUNG WOMEN 
WITH CERVICAL CANCER, BY CANCER STAGE
(Decade A n=273; Decade B n=310)
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There were 34 (11%) HIV positive patients and 83 (27%) HIV NP women in decade B that 
were alive with no evidence of disease at 60 months. HIV positive status decreases the 
probability of being alive with NED at 60 months (p<0,001). Comparisons between the 
decades were not credible due to decade A having an insufficient sample size. 
 
Of those patients who were HIV positive, 58% (7 patients) died of cancer at five years during 
decade A and 52% (53 patients) during decade B. This demonstrates no significant 
difference between the decades (p=0,68) despite the small sample cohort in decade A. 55% 
(143 patients) of patients who were HIV NP had died of cancer at five years in decade A and 
57% (118 patients) in decade B – this difference was noted not to be statistically significant 
(p=0,67). Death due to cancer at five-years was noted not to be significantly influenced by 
HIV status (p=0,43).  
 
Figure 18 : Distribution of 5-year disease outcomes among young women diagnosed with 














LFU Lost 2 4 16 2
Dead OTH 1 11 20 4
Dead CAN 7 53 143 118
Alive CAN 0 0 0 1



















DISTRIBUTION OF 5 YEAR DISEASE OUTCOMES AMONG YOUNG 
WOMEN WITH CERVICAL CANCER, BY HIV STATUS
(Decade A n=273; Decade B n=310)
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5-year survival outcome at Groote Schuur Hospital LE 33 
 
In Table 10, the proportion of young women surviving after 5 years with stage 1 cancer, has 
increased from decade A (average of 56%) to B (average of 80%). This is quite comparable to 
the FIGO statistics in Table 2, where, across all age groups, the average 5-year survival is 
89% in stage 1 women.  For those in this study with stage 2 cervical cancer, 5-year survival 
has decreased from 34% in decade A to 19% in decade B (corresponding average FIGO 5-
year survival in Table 2 of 70%). This is a marked decrease, not comparable to international 
standards. The 5-year survival for late-stage cancer patients has decreased from 9% during 
decade A to no survivors documented during decade B – this compared to an international 
average of 28% as per the FIGO 5-year survival in Table 2 for this subset of women. 
 
Table 10 : Percentage of young women (40 years and younger) alive after 5 years, 
according to each decade 
 
Stage 
% women alive after 5 years 
Decade A Decade B 
1a 61% 88% 
1b 50% 72% 
2 34% 19% 
3 and 4 9% 0% 
 
 
Time to recurrence 
 
In those patients with early-stage cervical cancer, time to recurrence was measured from 
the end date of treatment instituted, to the date of relapse of cervical cancer. This analysis, 
therefore, only included those patients who had relapsed. Figure 19 shows a comparison of 
this time in each decade according to stage and HIV status. 
 
Figure 19 shows that an improvement can be seen in time to recurrence for stage 1a 
patients with all patients in decade B not relapsing within 12 months (approximately 50% in 
decade A relapsed within 12 months). Young women with cervical cancer stage 1b in decade 
B also seem to be taking longer to recur compared to the previous decade. However, when 
tested the proportion of stage 1a and 1b relapses has not significantly improved from 
decade A to decade B (p=0,31). 
45 
 
When comparing the young women diagnosed with stage 2 cancer during decade A and B, 
the proportion of patients during decade A taking 3 months and less to recur, and those 
taking six to twelve months to recur, have not reduced significantly to the proportion 
depicted in decade B (p=0,23). The proportion of stage 2 patients recurring by 12 months or 
more during decades A and B differ only marginally. There is a statistically significant 
increase in the proportion of patients with stage 2 cancer from decade A to decade B who 
are taking three to six months to recur (p=0,04).  
 
 





Figure 20 displays the different time intervals to recurrence, according to patients who are 
HIV positive compared to those HIV NP, in each decade. An improvement can be noticed 
from decade A to decade B in those patients who are HIV positive, as the proportion of 
patients recurring during 6 – 12 months in decade A, improve to a later time to recurrence 



















0-3 months 0 0 2 0 1 1 0 0
3-6 months 0 0 3 2 1 7 2 0
6-12 months 1 0 4 3 5 4 3 0

























TIME TO RECURRENCE AMONG YOUNG WOMEN WITH CERVICAL CANCER, BY 
CANCER STAGE
(Decade A n=44, Decade B n=40)
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In decade B’s HIV NP cohort, there is an increase in the proportion of individuals taking 3 – 6 
months and 12 months and more, to recur. In this same subset of women, those taking less 
than 3 months and 6 – 12 months to recur have decreased in quantity. However, due to the 
small relapse sample size in this study, these trends cannot necessarily be extrapolated to 
the population (p=0,22). 
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3-6 months 1 2 5 7
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Approximately, one-fifth of all cervical cancer patients diagnosed during a ten-year period at 
GSH will affect young women forty years and younger. Of this group, about 17% on average 
will be thirty years and younger while the majority will be between thirty-one and forty 
years of age.  
 
The two decade-groups under study showed no difference in trend with regards to age: 
survival between the older age group and the younger age group of women with cervical 
cancer during decade A and B showed no noteworthy difference. No substantial difference 
in overall survival exists between the young population in both decades.   
 
There was no evidence to suggest that overall survival is dependent on the histological type. 
However, the sample cohort was not large enough to show the variation in the trend 
between the decades. 
 
Initial Hb at presentation in women 40 years and younger, showed no change in trend from 
decade A to B – however, this was the Hb level recorded at the first LE 33 visit and no 
further data was extracted to examine if patients had received prior transfusions of iron 
supplementation. 
 
Decade B showed more early-stage cancer than decade A. In this early-stage cervical cancer 
cohort, there is a trend toward more locally-advanced (stage 2) cancers in the more recent 
decade. The SA National cervical screening initiative rolled out in the year 2000, with the 
"30-40-50" routine pap smear screening rule brought into effect. This could account for the 
increase in the early-stage cancer identification and diagnosis rate that can be seen from 
decade A to decade B in this population subset. However, even though the number of early-
stage cancers detected has increased with subsequent decades, it is worrying to note that it 
is not the quantity of stage 1 disease that has climbed, but rather the proportion of stage 2 
cancers that have increased. This raises concern as it seems as if early stage 1 cancers, that 
could have possibly been detected by cytological abnormalities on a simple Pap smear are 
now going on to develop later-stage cancer before presenting to a healthcare institution. 
Alternatively, due to the decrease in the number of late-stage disease presenting in these 
young women during decade B, it is also possible that more late-stage disease is actually 
being detected at an earlier phase as stage 2 disease. This could possibly be due to the ’30-
40-50’ pap smear roll-out initiative, encouraging women to present themselves earlier to a 
healthcare institution. Further in-depth investigation to uncover the exact contributing 
factor for the rise in stage 2 disease is needed to clarify the results.  
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Currently, approximately 75% of women in developed countries have had some type of 
cervical cancer screening within the last 5 years, in contrast to less than 5% of women in the 
developing world.34 Thus, emphasis needs to be placed on screening young women – not 
only just screening but also screening of the correct population at the appropriate time is of 
vital importance. While cytological screening has lowered the incidence of invasive cervical 
cancer in many developed countries, this type of screening needs established laboratory 
services, trained pathologists, and a minimum of three visits for screening, review of 
abnormal cytology results and subsequent treatment thereof. In these low-resource 
environments, this strategy has proven difficult to implement and sustain.35,36,37 In such 
countries with limited resources, multiple alternatives to cytological testing is available – 
cervicography, VIA, VILI, DVI, HPV-testing as well as co-testing.38 Closer investigation into 
screen-and-treat options (e.g. cryotherapy after a VIA positive test result) for low-resource 
settings have proved widely beneficial and is an efficient and cost-effective manner in which 
to manage patients.39 
 
 
Regarding staging and markers of 'aggression' for cervical cancer, there has been a notable 
approximate 50% decrease in the proportion of patients presenting with early-stage 1a and 
1b cancer with tumours 4 cm and less from decade A to decade B. This specific subset of 
patients, allows for preferred surgical management. Surgery is superior to radiotherapy 
(either as a primary or adjuvant treatment) in this category of women, as they are still in 
their reproductive years, and by avoiding pelvic-radiation exposure their ovarian reserve 
and function can be preserved. However, with the decrease observed with the progressing 
decades – it seems that fewer patients get to use this ovarian-sparing management option.   
 
There has been a significant increase in the proportion of stage 2 cancers presenting with 
tumours 2 – 4cm in size in decade B; almost 3-fold that of decade A. There is a shift in the 
trend of the majority of young women, from smaller tumours (2cm or less) seen in decade A 
to tumours 2 to 4 cm in size in decade B. This could point to a developing trend of 
presentation of both, more locally-advanced and slightly larger tumour size in early-stage 
cancer rather than more stage 1 early-stage microscopic disease presenting.  
 
The proportion of women with late-stage cancer with and without hydronephrosis did not 
demonstrate any significant change in trend from decade A to decade B. The mean overall 
survival in patients with late-stage cancer and hydronephrosis has also not changed from 
decade A to decade B: the mean survival in stage 3b patients at approximately 1 year and in 
those stage 4 patients at approximately three and a half months on average, versus 28 





The subset of young women with late-stage cancer and unilateral parametrial involvement 
decreased. In contrast, bilateral parametrial involvement and PSW invasion had significantly 
increased from decade A to decade B. The mean overall survival in patients with parametrial 
involvement (unilateral and bilateral) as well as in patients with pelvic sidewall invasion, 
have had no change in trend from decade A to decade B – those with PSW involvement 
having the best mean survival at approximately 54 months on average. 
 
With reference to the type of treatment received during decade A, the majority of patients 
received treatment group 1 (surgery with or without EBRT, adjuvant vault brachytherapy or 
adjuvant EBRT and vault brachytherapy). The majority of patients in decade B however, 
received concurrent chemotherapy (treatment group 4), followed by treatment group 1. 
This shows the evident shift in management from the year 1999 onwards, where young 
women with cervical cancer in decade A, received mainly radiotherapy without 
chemotherapy, to decade B where patients received a combination of radiotherapy and 
chemotherapy.   
 
As cervical cancer treatment is stage-dependent, the majority of stage 1 disease in both 
decades received treatment group 1. Significantly more women in decade B with stage 2 
cancers received treatment group 2 or 4 compared to decade A, most likely due to the 
increase in the incidence of stage 2 cancers and the shift in management from radiotherapy 
alone to combined chemoradiation that occurred more so in the latter decade. 
 
Those patients who received treatment group W (surgery with or without radiotherapy) had 
the best probability of survival, followed by treatment group Y (concurrent chemotherapy) - 
attributed to the fact that the majority of early-stage cervical cancer fell into these two 
treatment groups. As alluded to earlier, treatment of stage 1 and some stage 2a cervical 
cancer is usually surgical (treatment group W) unless there are contraindications to surgery, 
which is when primary chemoradiation (treatment group Y) then becomes the treatment of 
choice in these patients. The different types of surgery can range from a cone biopsy for 
early-stage 1a disease to a radical hysterectomy (removal of the uterus, cervix, parametria 
and vaginal cuff) with bilateral pelvic lymph node dissection of the external iliac, internal 
iliac, obturator, and common iliac lymph nodes.40 Fertility-sparing options for surgery has 
become increasingly more common in the surgical treatment of early-stage disease (such as 
cone biopsy, trachelectomy or radical trachelectomy) for selected young individuals and 
with good results.41 However, patients who do not fulfil the criteria to be surgical candidates 
will then receive combined chemoradiation treatment. The addition of chemotherapy to 
radiotherapy offers a reasonably significant benefit on all outcomes (including survival, 
disease-free survival, local and distant recurrence as well as side effect profile) and for all 
stages of disease.42 Thus, the evidence-based change in trend from radiotherapy alone in 
this group of women to combined chemoradiation that can be seen from decade A to 
decade B. This particular subset of women are in their reproductive years, and with many 
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women wanting to start families at a later age, fertility-sparing options to preserve fertility 
as far as possible is important. Standard pelvic radiation doses can cause ovarian ablation, 
but oophoropexy (ovarian transposition) can assist with the preservation of fertility and 
ovarian function in such cases.43  
 
During both decades and across all durations (up to 60 months), stage 1 cervical cancers had 
the best probability of survival. Mean survival also improved in this subset - an average of 44 
months during decade A to 58 months during decade B. Although, there was no difference 
in overall survival in those young women with stage 2 cancer from decade A to B, there is a 
noteworthy deterioration in mean survival in these patients from 48 to 21 months in decade 
A to B, respectively. Late-stage cancer had the worst overall survival with no change in trend 
from decade A to B, with mean survival noted to have dropped from 2 years in decade A to 
3 months in decade B. 
 
 
Practically no difference in disease-free probability existed between each stage of cancer: 
1a, 1b and 2. Disease-free probability of survival for these early-stage cancers showed no 
difference between the decades either. 
 
There is no evidence of change in the proportion of patients during decade A that are ‘alive 
with NED’ and that ‘died of cancer’ when compared to that in decade B. However, the study 
data did not show significant evidence that survival outcomes do not differ between the 
decades under analysis. A higher proportion of young women with early-stage disease were 
alive with NED at 60 months during the later decade. Decade B also fared better with the 
number of patients suffering from cancer-related deaths decreasing in those with stage 1b 
and late-stage cancers. However, stage 2 patients during decade B did worse than during 
decade A, as a higher proportion of women suffered cancer-related deaths during decade B. 
 
This study demonstrated that time to recurrence in decade B when compared to decade A 
for stage 2 cancer patients, has increased in the 3 – 6 months category - indicating a 
deterioration, as more patients in the more recent decade are now taking a shorter interval 
to relapse than in the prior decade.  
 
When viewed in comparison to the FIGO statistics, stage 1 Groote Schuur Hospital cervical 
cancer patients seem to be in keeping with international 5-year survival trends. Our 
institution’s stage 2 and late-stage cancer patient’s 5-year survival trend has proven poorer 




Due to HIV testing only becoming a standard and routine practise during decade B 
(evidenced by a third of this population being HIV positive and 59% HIV negative), the 
majority of the HIV comparisons during decade A proved not credible. 
 
There is not enough convincing evidence in the data to show a difference in overall survival 
outcomes based on HIV status, for both decades under study. Mean survival in both HIV 
positive and NP women has decreased from decade A to decade B. Nevertheless, patients 
with a NP status have better mean survival than those that are status positive during both 
decades. HIV positive status was shown in this study to have decreased the probability of 
being alive with NED at 60 months significantly. Cancer-related deaths at 5 years are 
independent of HIV status.   
 
It was interesting to note that tumour size on presentation (for tumours less than 4 cm) in 
the latter decade, was influenced by HIV status. However, comparisons between HIV status 
and time to recurrence proved challenging to analyse constructively due to the small relapse 





















Although this study concentrated on a minimal subset of the total cervical cancer population 
(approximately 20%), it is this crucial cohort of women that represent young patients in 
their prime reproductive and adult years. With cervical cancer being a potentially curable 
disease if presented timeously, this specific group of patients should be the focus of primary 
and secondary prevention strategies. 
 
This study demonstrated that there is a trend toward the diagnosis of more locally-
advanced (stage 2) cervical cancer in young women, with worsening survival outcomes in 
the more recent decade. As the majority of staging was clinical, some stage 2 cancer 
patients could likely have been under-staged and could have been more advanced at the 
time of initial clinical assessment. The new 2018 revised FIGO staging for cervical cancer 
incorporates the use of CT (computed tomography) scans and MRI (magnetic resonance 
imaging), a move that could assist in improved staging and treatment outcomes. This finding 
ultimately indicates that more strategic efforts need to be focussed on primary and 
secondary preventative strategies to try and identify patients at an earlier point in time 
where they will have better overall survival and disease-free outcomes and in-turn assist 
with curbing the rising cervical cancer morbidity and mortality. Since the roll-out of the HPV 
vaccine in 2014 to school-going girls in South Africa, the effect of this primary preventative 
strategy on the incidence of cervical cancer is yet to be assessed.4  
 
This study seemed to show that there is a possible link between tumour size at presentation 
and HIV status, as well as a decreased probability of disease-free survival at 5 years if status 
positive. As the association between HIV and invasive cervical cancer is complex, additional 
details and information are needed to clarify these findings. HIV-positive women are up to 
five times more likely to be at risk for developing cervical cancer compared to those with a 
negative status.44 Knowing this, presents healthcare workers with a powerful opportunity 
for the development of a life-saving alliance between two critical global health burdens. By 
combining the approach to address both HIV and cervical cancer, potentially holds many 
significant benefits, of which the roll-out of the HPV vaccine is only a start. With the 
furthering success of ARV treatments and advances in HIV care, a critical opportunity exists 
to increase knowledge and raise awareness of symptoms, signs and risks of cervical cancer, 
promotion of safe-sex practices, knowing one's status and emphasizing the importance of 
getting tested as well as screening for cervical cancer at regular intervals. 
 
The analysis and review done in this retrospective audit lead the author to believe that a 
more focussed screening programme will prompt earlier diagnosis with subsequent 
appropriate and timeous treatment of cervical cancer, together with optimisation of 
comorbidities like HIV in this group of young patients will aid the burden of this potentially 
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Strengths, Limitations and Recommendations 
The strength of this study was the comparison between decades of outcomes and 5-year 
survival trends. This study, however, fell short in the fact that it was a retrospective audit 
and data obtained was occasionally missing or incomplete from the pre-existing database 
and CAC registration forms. The sample size was small, the study time-period was short, and 
the audit conducted at only one institution in the Western Cape. Due to the small sample 
size, different cancer stages were grouped together (eg. stage 2 rather than stage 2a and 
stage 2b) rather than analysed separately which would have yielded better information. 
Radiotherapy techniques have also improved with the passing of decades, which could have 
also had an impact on the outcomes demonstrated in this study. In this study, comparisons 
between the HIV positive cohort of patients to those grouped as ‘not positive’ (inclusive of 
HIV negative patients, untested patients and those patients with undocumented test 
results) could have possibly skewed data, especially if those patients in the latter were HIV 
positive. The author, therefore, recommends that these comparisons and trends be more 
accurately and closely examined as part of a larger, multi-centred, and national analysis to 
better clarify these findings confidently before extrapolating it to the population. 
 
Further finer details with reference to HIV (details of diagnosis, treatment regimens and 
viral load levels and trends), Hb (the level at first presentation to a healthcare facility, details 
of blood transfusions and oral or intravenous iron supplementation), Pap smear (date of the 
last test done and if the patient received the result), other risk factors (smoking, age at 
sexual debut, number of sexual partners, type of contraceptive use), late-stage disease 
(reasons why these patients present so late, their risk factors present, their follow-up course 
and how their quality of life fare) and treatment (type, side-effects, diagnosis-to-treatment 
time, duration of treatment received) are all critical details that would give more 
information and clarity to some aspects only touched upon in this study. Nonetheless, the 
findings in this small retrospective audit offer further hypothesis-generating data and serve 
to emphasize the importance of considering disease distribution, significant comorbidities 
like HIV status, the stage of cancer, tumour size and histology when determining 5-year 
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Glossary of Abbreviations:  
AIDS – Acquired Immune Deficiency Syndrome 
CAC – combined assessment clinic 
CDC – Centres for Disease Control 
CEDAW - Convention on the Elimination of All Forms of Discrimination Against Women  
CEO – Chief executive officer 
CIN – cervical intraepithelial neoplasia 
CT – computed tomography 
DoH – Department of Health 
DVI – direct visual inspection 
GLOBOCAN – Global Cancer Observatory  
GSH – Groote Schuur Hospital 
Hb – haemoglobin  
HCT – HIV counselling and testing 
HIV – Human Immunodeficiency Virus 
HOD – head of department 
HPV – Human Papilloma Virus 
LMIC – low- and middle- income countries 
MRI – magnetic resonance imaging 
NHLS – National Health Laboratory Service 
NP – not positive (inclusive of those patients who were HIV negative and those whose status was not specified) 
NS – not specified 
Pap Smear – Papanicolaou cervical smear test 
PMTCT – prevention of mother-to-child-transmission 
SA – South Africa 
SSA – Sub-Saharan Africa 
Stats SA – Statistics South Africa 
STI – sexually transmitted infection 
TOP – termination of pregnancy 
UCT – University of Cape Town 
VIA – visual inspection with aceto-acetic acid 









Appendix 2 : Department Consent from HOD 
